Navigation Links
ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
Date:8/30/2007

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- ConforMIS, a privately held medical device company dedicated to developing and marketing patient-specific orthopedic implants, today announced completion of its move to a new 15,000-sq.-foot headquarter facility in Burlington, MA.

The new facility was chosen to accommodate ConforMIS' rapid growth and marks the completion of the management team's efforts to move commercial operations to Massachusetts. The Burlington headquarter office combines operational functions that previously resided in Foster City, CA and Lexington, MA, including customer service, imaging services, and implant design. The facility will also allow ConforMIS to bring additional capabilities online in one location, such as manufacturing, rapid prototyping, product sterilization, packaging and shipping, and implant engineering and development.

"Our new headquarters will allow us to scale our operations to better support the rapid growth we have experienced over the last year and expect to see over the foreseeable future," said Patrick Hess, CEO of ConforMIS. "Not only will it accommodate the ongoing expansion of key company functions, it also gives us the ability to bring in new infrastructure that was not possible at our previous facilities."

The new offices are located at 2 Fourth Avenue, Burlington, MA 01803. The company's telephone numbers, including those for Imaging Services and Customer Service, remain the same.

About ConforMIS, Inc.

ConforMIS is a privately held medical device company whose mission is to provide best-in-class, minimally invasive implants for orthopedics and sports medicine through the use of its proprietary iFit Technology(TM). The iFit Technology is a patent-protected, software-enabled process for converting CT and MR imaging data into personalized, patient-specific implants. This "image-to-implant" technology allows for precisely sized and shaped implants that reduce or eliminate the need for cartilage or bone resection and radically simplify the surgical procedure. To date, the company has applied this technology to the knee joint and developed a comprehensive line of knee implants for all stages of osteoarthritis. For more information please visit http://www.conformis.com.

Contact:

Patrick Hess, CEO

(650) 286-4151 ext. 1102

Jong Lee, SVP Marketing

(781) 860-5111 ext. 1107

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE ConforMIS, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin spaceport committee moves closer to formation
2. Sonic Foundrys Mediasite moves to podcasts
3. Blogging moves to corporate America
4. A budget that moves Wisconsin forward
5. Merge eFilm corporate merger with Canadian firm moves ahead
6. Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters
7. Rayovac to Relocate Headquarters
8. RedPrairie Establishes Asia-Pacific Headquarters in Shanghai
9. Data centers: Buyers beware of over-hyped facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):